Related Experiment Video

Updated: Jul 7, 2026

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay
12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

CDC25A phosphatase: a rate-limiting oncogene that determines genomic stability

Dipankar Ray1, Hiroaki Kiyokawa

  • 1Department of Molecular Pharmacology and Biological Chemistry, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA.

Cancer Research
|March 5, 2008
PubMed

Insights

Restricting CDC25A, a key cell cycle regulator, limits cancer growth driven by HER2/neu-RAS without harming normal cells. This supports developing CDC25A inhibitors for cancer treatment.

Area of Science:

  • Oncology
  • Cell Biology
  • Molecular Biology

Background:

  • CDC25A is a phosphatase crucial for cell cycle progression and checkpoint control.
  • Overexpression of CDC25A is frequently observed in human cancers.
  • The HER2/neu-RAS oncogenic pathway is implicated in various tumor types.

Purpose of the Study:

  • To investigate the therapeutic potential of targeting CDC25A in cancer.
  • To determine if restricting CDC25A can inhibit tumorigenesis driven by the HER2/neu-RAS pathway.
  • To assess the impact of CDC25A restriction on normal cell division and viability.

Main Methods:

  • Genetic studies in a mouse model.
  • Analysis of tumorigenesis induced by the HER2/neu-RAS oncogenic pathway.
  • Evaluation of cell division and viability following CDC25A restriction.

Main Results:

  • Restricting CDC25A effectively limited tumorigenesis in the studied mouse model.
  • Tumorigenesis was specifically linked to the HER2/neu-RAS oncogenic pathway.
  • Normal cell division and viability were not compromised by CDC25A restriction.

Conclusions:

  • CDC25A is a viable therapeutic target for antitumor strategies.
  • Inhibiting CDC25A offers a promising approach for cancer treatment, particularly in HER2/neu-RAS-driven cancers.
  • Targeting CDC25A may provide a therapeutic window with minimal impact on healthy tissues.

More Related Videos

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols12:02

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols

Published on: June 6, 2017

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Concept Videos

DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.